Poly ADP ribose polymerase (PARP) inhibitor
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
Rucaparib has been used for:
· Antagonizes multidrug resistance (MDR) in doxorubicin and paclitaxel resistance cervical cancer cell lines by binding to the active site of ATP-binding cassette (ABC) transporters (Chen et al.).
· Cytotoxic to human cell lines with mutated BRCA1/2 (MDA-MB-436, HCC1937 and CAPAN-1) and to UACC3199 cells with epigenetically silenced BRCA1 but not to cell lines without BRCA1/2 mutations (MCF7, MDA-MB-231, HCC1937-BRCA1 and OSEC-2) or heterozygous for BRCA2 mutation (OSEC-1) (Drewet al.).
· Reduces growth of mouse xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 (Drew et al.).
· Concentration-dependent antiproliferative effects in many ovarian cancer cell lines with and without BRCA1/2 mutations (Ihnen et al.).
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Item added to your cart
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.